MMP3 and colorectal cancer: The tight suppression of MMP-3 (↓ 81.3% KAE, ↓ 83.3% cisplatin), as well as u-Plasminogen Activator/Urokinase (↓ 71.7% KAE, ↓ 74.8% cisplatin), directly impairs ECM degradation, cell migration, and metastatic spread—critical steps in colorectal cancer progression.